Protagonist Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 20, 2024, regarding the Company's 2024 Annual Meeting of Stockholders. The filing was signed on June 26, 2024, by Asif Ali, Executive Vice President and Chief Financial Officer.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Corporate Actions
The primary material change reported is the approval of an amendment to the Company's Amended and Restated Certificate of Incorporation. Key details include:
- Authorized Share Increase: Stockholders approved increasing authorized Common Stock from 90,000,000 to 180,000,000 shares.
- Total Authorized Shares: The total number of authorized shares increased from 100,000,000 to 190,000,000.
- Effective Date: The Certificate of Amendment was filed with the Delaware Secretary of State on June 21, 2024, and became effective immediately.
Voting Results and Governance
As of the record date (April 24, 2024), 58,643,133 shares were entitled to vote. All four proposals submitted were approved:
- Proposal 1 (Director Election): All three Class II nominees (Sarah A. O'Dowd, William D. Waddill, and Lewis T. Williams) were elected. Notably, Sarah A. O'Dowd received a significant number of withheld votes (19,687,632) compared to "For" votes (23,937,874).
- Proposal 2 (Executive Compensation): Advisory vote on named executive officer compensation was approved (33,929,884 For vs. 9,335,699 Against).
- Proposal 3 (Auditor Ratification): Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2024 with overwhelming support (49,293,711 For vs. 115,292 Against).
- Proposal 4 (Share Authorization): The amendment to increase authorized shares was approved (47,200,237 For vs. 278,523 Against).
Outlook, Risks, and Contingencies
The filing does not contain management commentary on future outlook, specific risks, contingencies, or unusual items beyond the standard corporate governance disclosures.
Investor Verification Checklist
- Verify the impact of the increased authorized share count (180M Common Stock) on potential future dilution.
- Review the definitive proxy statement filed on April 26, 2024, for detailed context on the significant number of withheld votes for director nominee Sarah A. O'Dowd.
- Confirm the effective date of the Certificate of Amendment (June 21, 2024) in Delaware state records.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial health metrics.